Board of directors

The main task of the Board of Directors, under the leadership of the Chairman, is to determine the company’s general policy and supervise its activities. The Board of Directors has five members.

Aly TalenRN

Aly Talen

Director

  • First appointed: 2005
 
Aly has a degree in general and psychiatric nursing with extensive nursing experience in a catheterization laboratory (Hamburg, Germany). She worked as a Clinical Research Associate and Project Manager for Omnicare Clinical Research, a Clinical Research Organization. She founded the CRO “Talen Clinical Trial Management” in 2001, which was acquired by genae associates in 2005.

Aly lived and worked in different countries which facilitates in the contact with different cultures. Her experience and network in the clinical field make her a credible and reliable partner in discussions with key opinion leaders and the medical industries. She is a talented communicator with a strong clinical research background.

Aly is all about providing clear and full support to customers, resulting in long-lasting relationships and repeat business opportunities.

Bart Segers

Bart Segers

Director

  • First appointed: 2005
  • Member of the Audit Committee
 
Bart Segers has been co-founder and CEO of genae since 2005. With a degree in telecommunications, he initially held engineering positions in the flight simulation department of Sabena (now Brussels Airlines) and Canon Europe. In 1993, his experience in laser technology facilitated the start in the medical field at Spectranetics, a US-based medical device manufacturer, where he later guided the Sales & Marketing team for Europe, the Middle East and Africa as General Manager until 2005.

Together with Aly Talen and private investors, he then founded genae, a global mid-size CRO with focus on medical devices. He currently rolls-out a merger and acquisition plan for the genae group and continues to expand the offices in the USA, Europe, the Middle East and Asia Pacific. January 2015 marked the integration of e-novex in the e-Solutions business unit of the genae Group.

Marc BosiersMD

Marc Bosiers

Director

  • First appointed: 2011
 
Marc Bosiers graduated in 1983 from the University of Leuven in Belgium. From 1983 till 1990, he specialized and became Supervisor at the Westfälische Wilhelms University in Münster where he worked at the Klinik für Anästhesiologie und operative Intensivmedizin and the Klinik für Allgemeine und Gefässchirurgie.

Dr. Bosiers has been head of the Department of Vascular Surgery at the St. Blasius Hospital in Dendermonde, Belgium since 1993. He has authored over 150 publications in peer-reviewed journals, he wrote two books, has a track record of more than 600 presentations and he holds several positions in national and international professional and scientific organizations. As principal investigator, he has led and participated in numerous clinical research programs in the field of endovascular therapy.

Dr. Bosiers is a proctor for endovascular strategies for renal revascularization, critical limb ischemia, carotid stenting, EVAR and infrapopliteal revascularization.
He is a member of the Deutsche Gesellschaft für Chirurgie, the Deutsche Gesellschaft für Gefässchirurgie, the Deutsche Gesellschaft für Flebologie, the Belgian Society for Vascular Surgery, the European Society for Vascular Surgery, the International Society of Endovascular Specialists, the Workgroup Endovascular Surgery of the Belgian Society for Vascular Surgery, the International Society for Vascular surgery, founding member of the Society of Industry Leaders and Honorary member of the Austrian Society for Vascular Surgery and the Swiss Society for Vascular Surgery.

Christoph Waer

Christoph Waer

Director

  • First appointed: 2016
  • Member of the Audit Committee
 
Christoph is an Investment Manager at Korys, focusing on the fund's investments in the life science sector. In this capacity, he currently also represents Korys on the board of Agendia, Bluebee and MyCartis.

Prior to joining Korys, Christoph worked in the Corporate Finance department of Fortis Bank in France (now BNP Paribas) and at iPierian, a San Francisco biotech start-up company.

William WynsMD, PhD

William Wyns

Non-Executive Director

  • First appointed: 2011
 
William Wyns graduated in 1976 from the University of Leuven in Belgium where he trained as a cardiologist until 1981. He then joined the Thorax Center in Rotterdam where he was actively involved with the first applications of nuclear cardiology, thrombolysis and coronary dilatation. After spending two years as a Visiting Associate Professor of Radiological Sciences at UCLA, Dr. Wyns returned to the University of Louvain in Brussels where he directed the cardiac PET programme and became Clinical Professor of Cardiology. His research focused on the regulation of coronary blood flow and cardiac metabolism in ischemic heart disease.

Since 1994, Dr. Wyns has been the co-Director of the Cardiovascular Center Aalst and is active as an interventional cardiologist. Recently, he has been involved with the clinical applications of non-invasive coronary angiography with the use of multi-slice computed tomography, as well as invasive coronary imaging (IVUS and OCT). He has authored over 400 publications in peer-reviewed journals and holds several positions in national and international professional and scientific organizations.

Dr Wyns has been a Board member of the World Heart Federation and the European Society of Cardiology. He is past-President of EAPCI, the European Association for Percutaneous Cardiovascular Interventions.

Dr. Wyns is currently Chairman of PCR, Course Director of EuroPCR and Course Director of AfricaPCR.

Youri SteverlynckLLM

Youri Steverlynck

Non-Executive Director

  • First appointed: 2016
 
Youri Steverlynck is a partner at the law firm Lexeco and a curator at the Commercial Court of Antwerp. He gained a degree in law from the KUL in 1996 and was appointed in 1997 to the Bar of Antwerp. From 2002 to 2008 he held various management positions in companies in Belgium and abroad, first at the corporate affairs department, later in the marketing department and finally as CEO. In 2009 he became a full-time partner at Lexeco. Youri focuses on corporate law. He specializes in restructuring and insolvency law and has extensive experience in corporate law, mergers and acquisitions, shareholder disputes, director liability and contracts. He has particular expertise in finance & securities.

In recent years, Youri frequently served as liquidator in complex dissolutions of companies. He enjoys a broad international experience in commercial negotiations, sector regulation and in dealing with public authorities. One of Youri’s key differentiatiors, in supporting an entrepreneur as a lawyer, is actually thinking like an entrepreneur.

Ask the expert

Please submit your question